OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)

South Korea · Delayed Price · Currency is KRW

6,270.00

+250.00 (4.15%)

At close: Oct 1, 2026

Market Cap	110.64B -5.1%
Revenue (ttm)	94.47B +14.1%
Net Income	13.75B +44.6%
EPS	835.83 +34.4%
Shares Out	17.65M
PE Ratio	7.50
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	144,315
Open	5,960.00
Previous Close	6,020.00
Day's Range	5,950.00 - 6,440.00
52-Week Range	4,610.00 - 20,750.00
Beta	-0.05
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 23, 2026

About OPTUS Pharmaceutical

OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea. [Read more]

Industry Pharmaceutical Preparations

Founded 2002

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 131030

Full Company Profile

Financial Performance

In 2025, OPTUS Pharmaceutical's revenue was 87.16 billion, an increase of 6.42% compared to the previous year's 81.90 billion. Earnings were 11.36 billion, an increase of 10.18%.

Financial Statements